Iparomlimab and Tuvonralimab Combined With Platinum-Based Chemotherapy for Neoadjuvant Treatment of Cervical Cancer

NCT06986057 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Cervical Cancer
Neoadjuvant Therapy

Interventions

DRUG: Iparomlimab and tuvonralimab (QL1706) combined with platinum-based chemotherapy

Sponsor

Shandong Tumor Hospital